The inclusion criteria for the clinical trials discussed in this review required that the study (1) included participants diagnosed with a neurodegenerative condition with evidence of cognitive decline, such as AD, (2) utilized RSG as the only form of treatment for AD, (3) utilized RSG in conjunction with standard drugs commonly used to treat AD, such as acetylcholinesterase inhibitors (AChEIs) like donepezil and (4) studies that provided results. This evidence concerns the gene ACHE and Alzheimer disease.